Structural Formula (Lev26 0002 01)
Chemical structure diagram of levetiracetam showing its molecular configuration with labeled bonds and functional groups.*
Levetiracetam Injection
Product Images NDC 65219-042
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 65219-042). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Lev26 0002 02)
A bar graph comparing the percentage of patients among three groups: Placebo, Levetiracetam 1,000 mg/day, and Levetiracetam 3,000 mg/day. The percentages are approximately 7.4% for Placebo, 37.1% for Levetiracetam 1,000 mg/day, and 39.6% for Levetiracetam 3,000 mg/day, with statistical significance indicated for the latter two versus placebo.*
Figure 2 (Lev26 0002 03)
A bar graph showing the percentage of patients experiencing an outcome for three groups: Placebo (6.3%, N=111), Levetiracetam 1,000 mg/day (20.8%, N=106), and Levetiracetam 2,000 mg/day (35.2%, N=105). Statistically significant differences from placebo are indicated for both Levetiracetam groups.*
Figure 3 (Lev26 0002 04)
Bar chart comparing the percentage of patients for placebo and Levetiracetam 3,000 mg/day groups. The chart shows 14.4% for placebo (N=104) and 39.4% for Levetiracetam (N=180), with an asterisk noting statistical significance versus placebo. The y-axis represents the percentage of patients.*
Figure 4 (Lev26 0002 05)
A bar graph comparing the percentage of patients between placebo and levetiracetam groups. The placebo group (N=84) shows 45.2%, while the levetiracetam group (N=79) shows 72.2%, with a noted statistical significance between the groups.*
Fresenius Kabi Logo (Lev26 0002 06)
Package Label (PRINCIPAL DISPLAY – Levetiracetam 500 mg in 100 mL Bag Label)
Levetiracetam 500 mg in 100 mL (5 mg per mL) injection in 0.82% Sodium Chloride for intravenous infusion. The label includes usage instructions, storage conditions (20° to 25°C), manufacturer Fresenius Kabi USA, LLC, and specifies that it is a single-dose dual port bag made in Norway. Additional caution and composition details are also present.*
Package Label (PRINCIPAL DISPLAY – Levetiracetam in 0.82% Sodium Chloride Injection Shipper Label)
Label for Levetiracetam injection in 0.82% sodium chloride injection, containing 500 mg in 100 mL (5 mg/mL). The package includes 24 single-dose 100 mL bags. Manufactured for Fresenius Kabi USA, LLC, Lake Zurich, IL, made in Norway. The label includes storage instructions, caution for sterility checks, and barcodes.*
Package Label (PRINCIPAL DISPLAY – Levetiracetam 1,000 mg in 100 mL Bag Label)
Levetiracetam injection 10 mg/mL in 0.75% Sodium Chloride Injection, 100 mL vial by Fresenius Kabi USA, LLC. The label states 1,000 mg in 100 mL, for intravenous infusion only, with directions for use and storage between 20° to 25°C. Manufactured in Norway with specific usage and safety instructions.*
Package Label (PRINCIPAL DISPLAY – Levetiracetam in 0.75% Sodium Chloride Injection Shipper Label)
Levetiracetam 10 mg/mL in 0.75% Sodium Chloride Injection, 1,000 mg in 100 mL single-dose bags. The label indicates a package of 24 x 100 mL bags for intravenous infusion, manufactured for Fresenius Kabi USA, LLC. Storage instructions and caution regarding product handling are also included.*
Package Label (PRINCIPAL DISPLAY – Levetiracetam 1,500 mg in 100 mL Bag Label)
Levetiracetam 1500 mg in 100 mL (15 mg/mL) intravenous infusion injection label. Contains active ingredient levetiracetam with sodium chloride, glacial acetic acid, and sodium acetate in a buffered solution. For intravenous infusion only, to be used immediately after removal from overwrap and infused over 15 minutes. Manufactured by Fresenius Kabi USA, LLC, made in Norway. Storage instructions and cautions included on the label.*
Package Label (PRINCIPAL DISPLAY – Levetiracetam in 0.54% Sodium Chloride Injection Shipper Label)
Label for Levetiracetam 1,500 mg in 100 mL (15 mg/mL) injection in 0.54% sodium chloride. The product is provided as 24 single-dose 100 mL bags, manufactured by Fresenius Kabi USA, LLC in Norway. The label includes storage instructions and a caution about checking for leaks after removing the overwrap.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
